A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a global, randomized, controlled, open-label Phase 3 study designed to assess the
long-term efficacy and safety of UGN-102 (mitomycin) for intravesical solution with or
without (±) transurethral resection of bladder tumors (TURBT) versus TURBT alone for the
treatment of patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG
IR NMIBC).